This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration on Monday expanded ...

The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating Enhertu in combination with ...

Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer, ...

Daiichi Sankyo has announced the dosing of first patient in the DESTINY-Ovarian01 Phase III trial’s randomisation phase, ...

The federal appeals court has now reversed the 2022 verdict upholding the '039 patent, thereby vacating the Texas court's ...

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by AstraZeneca in the DESTINY-Endometrial01 phase 3 trial. AstraZeneca is ...

The Food and Drug Administration on Friday approved AstraZeneca and Daiichi Sankyo’s Datroway for use in people with a common type of breast cancer that has advanced despite two earlier lines of ...

(Reuters) -AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment for ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast cancer ...